FPH – UBS rates the stock as Sell

After reviewing the Vapotherm results, UBS believes the competitive threat to Fisher & Paykel is modest.

The company’s market position appears stable, although Vapotherm’s focus on emergency departments, where it has a better offering for undifferentiated respiratory distress, needs to be monitored.

NZ$12.60 target, Sell reiterated.

Sector: Health Care Equipment & Services.

Current Price is $14.27. Target price not assessed.

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →